StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a report released on Tuesday. The firm issued a sell rating on the stock.

Oragenics Stock Performance

NYSE OGEN traded up $0.32 on Tuesday, hitting $1.40. The stock had a trading volume of 1,739,745 shares, compared to its average volume of 185,378. The firm’s 50-day simple moving average is $1.25. Oragenics has a one year low of $0.86 and a one year high of $7.74. The stock has a market cap of $6.27 million, a PE ratio of -0.16 and a beta of 0.50.

Oragenics (NYSE:OGEN) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new stake in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the SEC. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.